Skip to content
Study details
Enrolling now

Effect of Azeliragon Combined With Stereotactic Radiation Therapy in Patients With Brain Metastases

Baptist Health South Florida
NCT IDNCT05789589ClinicalTrials.gov data as of Apr 2026
Phase

Phase 1/2

Target enrollment

46

Study length

about 3.8 years

Ages

18+

Locations

1 site in FL

About this study

This trial is testing a treatment with azeliragon and stereotactic radiation therapy for brain metastases. The goal is to see if this combination improves tumor shrinking and keeps tumors controlled longer.

Based on ClinicalTrials.gov records.

What participants do

  • 1.Receive Stereotactic radiosurgery
  • 2.Take Azeliragon
  • 3.Take Corticosteroid
PhasePhase 1/Phase 2
DrugCorticosteroid

Participation effort

Estimated from trial records. Details can vary by site.

Time + visits
Low15%
Logistics
Moderate50%

Logistics difficulty varies by site location and availability.

Trial highlights

Treatment details

Auto-extracted from trial records to preview treatments and outcomes.

Drug classes

corticosteroid

Endpoints

Secondary: CNS treatment-related adverse events, Change in QOL using EORTC QLQ-BN20, Change in patient-reported outcomes (PROs), Change in quality of life (QOL) using EORTC QLQ-C30, Early brain metastases response rate, Intracranial objective response rate

Procedures

radiation

Body systems

Oncology